FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 260 filers reported holding FATE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,187,000 | -16.4% | 52,950 | -7.6% | 0.01% | -21.4% |
| Q2 2022 | $1,420,000 | -86.8% | 57,320 | -56.1% | 0.01% | -86.7% |
| Q1 2021 | $10,775,000 | -4.7% | 130,688 | +5.1% | 0.10% | -17.3% |
| Q4 2020 | $11,309,000 | +155.5% | 124,368 | +12.3% | 0.13% | +95.4% |
| Q3 2020 | $4,427,000 | +21.8% | 110,747 | +4.5% | 0.06% | +32.7% |
| Q2 2020 | $3,636,000 | +19.1% | 105,979 | -22.9% | 0.05% | +4.3% |
| Q1 2020 | $3,052,000 | +2.5% | 137,433 | -9.7% | 0.05% | +104.3% |
| Q4 2019 | $2,978,000 | +47.1% | 152,157 | +16.7% | 0.02% | +43.8% |
| Q3 2019 | $2,025,000 | -26.9% | 130,386 | -4.4% | 0.02% | -23.8% |
| Q2 2019 | $2,770,000 | +1.2% | 136,434 | -12.5% | 0.02% | +10.5% |
| Q1 2019 | $2,738,000 | +43.1% | 155,838 | +4.5% | 0.02% | +26.7% |
| Q4 2018 | $1,913,000 | +24.2% | 149,103 | +57.7% | 0.02% | +50.0% |
| Q3 2018 | $1,540,000 | +77.0% | 94,532 | +23.2% | 0.01% | +66.7% |
| Q2 2018 | $870,000 | – | 76,714 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |